volociximab
atezolizumab
besilesomab
acrixolimab
fontolizumab
tislelizumab
inotuzumab ozogamicin
ravulizumab
zalutumumab
olaratumab
pidilizumab
amlitelimab
brolucizumab
etaracizumab
sibrotuzumab
gevokizumab
abagovomab
ozogamicin
-lim-
bivatuzumab
intrabody
olendalizumab
lexatumumab
antimonoclonal
-toxa-
ipilimumab
agonistic monoclonal antibody
dalotuzumab
-zumab
tigatuzumab
immunochemiluminometric
rapid antigen test
tabalumab
durvalumab
Forssman antibody
microlymphocytotoxicity
heterophile antibody
heterophil antibody
brodalumab
immunostrip
lenzilumab
immunofluorescence
talacotuzumab
immunolabeling
bectumomab
robatumumab
siltuximab
ocrelizumab
-o-
antinucleosome